We led trials establishing the effectiveness of the chemotherapy drug carboplatin – discovered at the ICR – in triple-negative breast cancer, and of the targeted drug palbociclib in advanced, metastatic breast cancer.
Recently, results from the OlympiA trial showed that using the targeted drug olaparib to treat some women with early stage breast cancer and mutations in their BRCA genes reduced their risk of breast cancer coming back by 42 per cent.
We are developing new tests to detect breast cancer and predict which patients are likely to see their disease come back, and spread.
For example, we pioneered the development of ‘liquid biopsies’ – blood tests that can detect the spread of cancer more quickly.
Recent results from the PlasmaMATCH trial have shown that liquid biopsies can match women with breast cancer to targeted drugs based on their specific mutations.
We have transformed radiotherapy treatment for breast cancer.
Together with The Royal Marsden, we led the START trial, which showed that women could safely undergo fewer, larger doses of chemotherapy with reduced side effects, reducing standard treatment from 25 doses over five weeks, to 15 doses over three weeks.
More recently, the FAST-Forward trial showed that the course could be further reduced to just one week, with the same benefits, for women with early-stage breast cancer.
Support our research